Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ADVIL versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ADVIL versus CHILDREN S IBUPROFEN.
CHILDREN'S ADVIL vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to decreased pain, inflammation, and fever through peripheral and central mechanisms.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
Terminal elimination half-life is 1.9–2.3 hours in children. In neonates, half-life is prolonged (up to 6 hours). Clinical context: Requires dosing every 6–8 hours for sustained antipyresis.
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal excretion of conjugated metabolites (glucuronide and sulfate) accounts for ~90% of the administered dose. Less than 5% is excreted unchanged in urine. Biliary/fecal elimination is minor (<5%).
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category C
Category D/X
NSAID
NSAID